ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment

Introduction:The outcome of glioblastoma (GBM) is improving recently, but still only temozolomide and bevacizumab (BEV) are recognized as the effective agents that are reimbursed in Japan. On large clinical trials, BEV prolonged progression free survival (PFS) but the remaining survival period from...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Miyu, Takahashi, Masamichi, Yanagisawa, Syunsuke, Ono, Makoto, Miyakita, Yasuji, Tamura, Yukie, Kawauchi, Daisuke, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664617/
http://dx.doi.org/10.1093/noajnl/vdab159.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664617/
http://dx.doi.org/10.1093/noajnl/vdab159.036

Ejemplares similares